CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 46 enrolled
Drug / intervention
Nebulized 5% Hypertonic salinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04765033
NCT04765033Phase 4Completed
CompareCT.gov

Efficacy of Nebulised 5% Hypertonic Saline in Children With Chronic Suppurative Lung Disease

University of Malaya·interventional·Posted Feb 21, 2021·Updated Dec 1, 2023

In Brief

A Phase 4 clinical trial evaluating Nebulized 5% Hypertonic saline for Bronchiectasis. Completed, enrolled 46 participants across 1 site.

Detailed Summary

To determine the efficacy of nebulized 5% hypertonic saline on cough severity and quality of life, in children with non-CF CSLD. Secondary Aims: To determine the: 1. Efficacy of nebulized 5% hypertonic saline on airway microbiome, pulmonary exacerbation rate, healthcare utilization, and rescue antibiotics. 2. Efficacy of nebulized 5% hypertonic saline on lung function 3. Adverse effects of nebulized 5% hypertonic saline in children

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBronchiectasis
CountriesMalaysia
Collaborators--

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedFeb 21, 2021
Enrollment StartFeb 4, 2021
Primary CompletionAug 28, 2023
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 5.4 years ago

Interventions

Nebulized 5% Hypertonic salinedrug

nebulized 0.9% saline